David K. Chang

47.7k total citations · 2 hit papers
90 papers, 3.2k citations indexed

About

David K. Chang is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, David K. Chang has authored 90 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 41 papers in Cancer Research and 29 papers in Molecular Biology. Recurrent topics in David K. Chang's work include Pancreatic and Hepatic Oncology Research (55 papers), Cancer Genomics and Diagnostics (36 papers) and Renal cell carcinoma treatment (12 papers). David K. Chang is often cited by papers focused on Pancreatic and Hepatic Oncology Research (55 papers), Cancer Genomics and Diagnostics (36 papers) and Renal cell carcinoma treatment (12 papers). David K. Chang collaborates with scholars based in United Kingdom, Australia and United States. David K. Chang's co-authors include Andrew V. Biankin, Peter J. Bailey, Eric A. Collisson, James G. Kench, Neil D. Merrett, Amber L. Johns, Christopher J. Scarlett, Stephan B. Dreyer, Sean M. Grimmond and Anthony J. Gill and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

David K. Chang

89 papers receiving 3.2k citations

Hit Papers

Molecular subtypes of pancreatic cancer 2019 2026 2021 2023 2019 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular subtypes of pancreatic cancer
    2019 530 citations Peter J. Bailey, David K. Chang et al. profile →
  2. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
    2020 261 citations David K. Chang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David K. Chang United Kingdom 29 2.3k 1.2k 1.0k 692 546 90 3.2k
Zhongwu Li China 30 1.7k 0.7× 1.2k 1.0× 683 0.7× 665 1.0× 969 1.8× 177 3.4k
Susumu Saigusa Japan 33 1.5k 0.6× 1.4k 1.1× 1.1k 1.1× 601 0.9× 602 1.1× 120 3.2k
Darren R. Carpizo United States 27 1.4k 0.6× 1.5k 1.2× 715 0.7× 433 0.6× 325 0.6× 80 3.0k
Yoon‐La Choi South Korea 35 1.6k 0.7× 1.4k 1.2× 1.1k 1.1× 372 0.5× 930 1.7× 125 3.7k
Jean‐Sébastien Frenel France 26 1.4k 0.6× 801 0.6× 708 0.7× 284 0.4× 809 1.5× 188 2.7k
Shunchang Jiao China 30 1.9k 0.8× 1.1k 0.9× 655 0.6× 278 0.4× 977 1.8× 144 3.4k
Eric Santoni‐Rugiu Denmark 35 1.2k 0.5× 1.7k 1.4× 681 0.7× 524 0.8× 757 1.4× 108 3.3k
Wentao Yang China 34 1.7k 0.8× 1.4k 1.1× 1.2k 1.2× 310 0.4× 590 1.1× 173 3.8k
Igor Astsaturov United States 32 1.1k 0.5× 1.2k 1.0× 512 0.5× 411 0.6× 496 0.9× 97 2.7k
Björn Nodin Sweden 32 1.5k 0.6× 1.0k 0.8× 594 0.6× 479 0.7× 579 1.1× 118 2.8k

Countries citing papers authored by David K. Chang

Since Specialization
Citations

This map shows the geographic impact of David K. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David K. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David K. Chang more than expected).

Fields of papers citing papers by David K. Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David K. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David K. Chang. The network helps show where David K. Chang may publish in the future.

Co-authorship network of co-authors of David K. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of David K. Chang. A scholar is included among the top collaborators of David K. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David K. Chang. David K. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chang, David K., et al.. (2025). The biological function and mechanism of action of circRNA as a potential target in colorectal cancer. Critical Reviews in Oncology/Hematology. 213. 104828–104828. 2 indexed citations
2.
Chang, David K., et al.. (2025). Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review. Western Journal of Emergency Medicine. 26(2). 210–218. 3 indexed citations
3.
Zhuravleva, Ekaterina, Monika Lewińska, Colm J. O’Rourke, et al.. (2024). Mutational signatures define immune and Wnt-associated subtypes of ampullary carcinoma. Gut. 74(5). 804–814. 1 indexed citations
4.
Fey, Sigrid K., Arafath K. Najumudeen, Catriona A. Ford, et al.. (2024). KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. Cancer Research. 85(2). 251–262. 4 indexed citations
5.
6.
Phillips, Matthew, et al.. (2024). Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study. Frontiers in Neurology. 14. 1329541–1329541. 8 indexed citations
7.
Wright, Thomas A., Yuan Yan Sin, Katharine Herbert, et al.. (2024). Disruption of the pro-oncogenic c-RAF–PDE8A complex represents a differentiated approach to treating KRAS–c-RAF dependent PDAC. Scientific Reports. 14(1). 8998–8998. 1 indexed citations
8.
Huisman, Henkjan, John J. Hermans, Geert Litjens, et al.. (2023). Artificial Intelligence in Pancreatic Ductal Adenocarcinoma Imaging: A Commentary on Potential Future Applications. Gastroenterology. 165(2). 309–316. 10 indexed citations
9.
10.
Pennel, Kathryn A.F., Jean A. Quinn, Colin Nixon, et al.. (2022). CXCL8 expression is associated with advanced stage, right sidedness, and distinct histological features of colorectal cancer. The Journal of Pathology Clinical Research. 8(6). 509–520. 7 indexed citations
11.
Head, PamelaSara E., Yong Chen, Jessica L. Schneller, et al.. (2022). Aberrant methylmalonylation underlies methylmalonic acidemia and is attenuated by an engineered sirtuin. Science Translational Medicine. 14(646). eabn4772–eabn4772. 30 indexed citations
12.
Madamsetty, Vijay Sagar, Ramcharan Singh Angom, Shamit K. Dutta, et al.. (2021). Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS. Cancers. 13(16). 4048–4048. 6 indexed citations
13.
Dreyer, Stephan B., David K. Chang, Peter J. Bailey, & Andrew V. Biankin. (2017). Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. Clinical Cancer Research. 23(7). 1638–1646. 128 indexed citations
14.
Bailey, Peter J., David K. Chang, Marie‐Andrée Forget, et al.. (2016). Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6(1). 35848–35848. 117 indexed citations
15.
Humphrey, Emily S., Shih‐Ping Su, Adnan Nagrial, et al.. (2016). Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling. Molecular & Cellular Proteomics. 15(8). 2671–2685. 26 indexed citations
16.
Jamieson, Nigel B., Sean M. Grimmond, Andrew V. Biankin, & David K. Chang. (2014). Pancreatic cancer: challenges for therapeutic development. ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam). 1 indexed citations
17.
Chang, David K., Sean M. Grimmond, & Andrew V. Biankin. (2014). Pancreatic cancer genomics. Current Opinion in Genetics & Development. 24. 74–81. 45 indexed citations
18.
Cao, Ying, Luke H. Hoeppner, Yan Guo, et al.. (2013). Neuropilin-2 Promotes Extravasation and Metastasis by Interacting with Endothelial α5 Integrin. Cancer Research. 73(14). 4579–4590. 86 indexed citations
19.
Chang, David K. & Cheryl L. Jorcyk. (2006). Role of oncostatin M (OSM) in prostate cancer. Cancer Research. 66. 819–819. 1 indexed citations
20.
Chang, David K. & William Ross. (2004). Endoscopic retrieval of a teaspoon from the stomach. ANZ Journal of Surgery. 74(11). 1013–1014. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhongwu Li Breakdown of academic impact, for papers by Susumu Saigusa Breakdown of academic impact, for papers by Darren R. Carpizo Breakdown of academic impact, for papers by Yoon‐La Choi Breakdown of academic impact, for papers by Jean‐Sébastien Frenel Breakdown of academic impact, for papers by Shunchang Jiao Breakdown of academic impact, for papers by Eric Santoni‐Rugiu Breakdown of academic impact, for papers by Wentao Yang Breakdown of academic impact, for papers by Igor Astsaturov Breakdown of academic impact, for papers by Björn Nodin
Rankless by CCL
2026